March 22, 2021
KM Biologics, a Meiji group company, said on March 19 that it has begun formulation work on AstraZeneca’s COVID-19 vaccine AZD1222, which is pending approval in Japan. The two companies signed a contract manufacturing agreement in February. Under the agreement,...read more